このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Epigenomics 将来の成長

Future 基準チェック /06

Epigenomicsの収益は年間150%で減少すると予測されていますが、年間利益は年間103.5%で増加すると予想されています。EPS は年間104.4%で増加すると予想されています。

主要情報

103.5%

収益成長率

104.4%

EPS成長率

Biotechs 収益成長	30.9%
収益成長率	-150.0%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	06 May 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

XTRA:ECX - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2025	N/A	0	N/A	N/A	1
12/31/2024	N/A	-1	N/A	N/A	1
12/31/2023	0	-4	-6	-6	N/A
9/30/2023	1	-18	-8	-8	N/A
6/30/2023	0	-16	-14	-13	N/A
3/31/2023	1	-15	-13	-12	N/A
12/31/2022	1	-17	-11	-11	N/A
9/30/2022	1	-7	-10	-9	N/A
6/30/2022	6	-3	-6	-6	N/A
3/31/2022	6	-4	-5	-5	N/A
12/31/2021	6	-2	-4	-4	N/A
9/30/2021	6	-3	-6	-6	N/A
6/30/2021	1	-9	-8	-8	N/A
3/31/2021	1	-10	-9	-9	N/A
12/31/2020	1	-12	-10	-10	N/A
9/30/2020	1	-16	-10	-10	N/A
6/30/2020	1	-16	-11	-11	N/A
3/31/2020	1	-17	-13	-12	N/A
12/31/2019	1	-17	-14	-14	N/A
9/30/2019	1	-14	-15	-14	N/A
6/30/2019	1	-14	-14	-14	N/A
3/31/2019	2	-12	-12	-12	N/A
12/31/2018	2	-13	-10	-10	N/A
9/30/2018	2	-11	-10	-10	N/A
6/30/2018	2	-10	-10	-9	N/A
3/31/2018	2	-11	-11	-11	N/A
12/31/2017	2	-10	-10	-10	N/A
9/30/2017	3	-9	N/A	-12	N/A
6/30/2017	3	-10	N/A	-14	N/A
3/31/2017	4	-9	N/A	-12	N/A
12/31/2016	4	-11	N/A	-13	N/A
9/30/2016	3	-11	N/A	-10	N/A
6/30/2016	3	-11	N/A	-8	N/A
3/31/2016	2	-10	N/A	-8	N/A
12/31/2015	2	-9	N/A	-8	N/A
9/30/2015	2	-11	N/A	-9	N/A
6/30/2015	2	-10	N/A	-9	N/A
3/31/2015	1	-10	N/A	-8	N/A
12/31/2014	2	-9	N/A	-7	N/A
9/30/2014	2	-8	N/A	-7	N/A
6/30/2014	2	-8	N/A	-6	N/A
3/31/2014	2	-8	N/A	-6	N/A
12/31/2013	2	-7	N/A	-7	N/A
9/30/2013	1	-8	N/A	-9	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ECX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ECX今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: ECX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ECX来年は収益がないと予測されています。

高い収益成長: ECX来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ECXの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Epigenomics 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target increased by 227% to €52.65

Consensus revenue estimates fall by 11%

Consensus revenue estimates decrease by 11%

Consensus revenue estimates increase by 139%

Price target increased by 9.1% to €6.00

Price target increased to €1.17

Recent updates

New major risk - Financial position

New minor risk - Financial data availability

Price target increased by 227% to €52.65

Consensus revenue estimates fall by 11%

Consensus revenue estimates decrease by 11%

Epigenomics AG, Annual General Meeting, May 29, 2024

New Day Diagnostics, LLC acquired Substantially all of Assets of Epigenomics AG for $9.8 million.

Consensus revenue estimates increase by 139%

Second quarter 2023 earnings released: €0.62 loss per share (vs €0.32 loss in 2Q 2022)

Now 30% undervalued

New Day Diagnostics, LLC entered into an asset purchase agreement to acquire Substantially all of Assets of Epigenomics AG.

Now 23% undervalued

A Look At The Intrinsic Value Of Epigenomics AG (ETR:ECX1)

Epigenomics Shares Surge on Talks to Sell Nearly All Assets for $11.5m

Price target increased by 9.1% to €6.00

First quarter 2023 earnings released: €1.31 loss per share (vs €0.67 loss in 1Q 2022)

Epigenomics AG Announces Resignation of Andrew Lukowiak from the Company and the Executive Board Effective May 31, 2023

Full year 2022 earnings released: €2.96 loss per share (vs €0.87 loss in FY 2021)

Price target increased to €1.17

Consensus forecasts updated

No longer forecast to breakeven

Third quarter 2022 earnings released

Epigenomics AG to Report Q3, 2023 Results on Nov 09, 2023

Epigenomics Ag Reaffirms Revenue Guidance for the Full Year 2022

Second quarter 2022 earnings released

Price target decreased to €0.98

Epigenomics AG Confirms Outlook for Fiscal Year 2022

Price target increased to €1.07

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Epigenomics AG Confirms Earnings Guidance for the Year 2022

Price target decreased to €0.95

No longer forecast to breakeven

No longer forecast to breakeven

Price target decreased to €0.95

Third quarter 2021 earnings released: EPS €0.23 (vs €0.47 loss in 3Q 2020)

Price target decreased to €1.14

New Horizon Health Limited (SEHK:6606) entered into an agreement to acquire certain non-essential biological samples from Epigenomics AG (XTRA:ECX) for $6.7 million.

Second quarter 2021 earnings released: €0.21 loss per share (vs €0.57 loss in 2Q 2020)

Price target decreased to €1.44

We're Keeping An Eye On Epigenomics' (ETR:ECX) Cash Burn Rate

Consensus forecasts updated

Forecast to breakeven in 2023

First quarter 2021 earnings released: €0.20 loss per share (vs €0.55 loss in 1Q 2020)

Epigenomics AG Announces Earnings Guidance for the Year 2021

Consensus forecasts updated

Consensus forecasts updated

Epigenomics AG Provides Earnings Guidance for the Year 2021

New 90-day low: €2.30

When Will Epigenomics AG (ETR:ECX) Breakeven?

Price target lowered to €16.27

Epigenomics AG Announces Resignation of Jorge Garces as Executive Board Member Effective January 31, 2021

Epigenomics Ag Announces the U.S. Centers for Medicare & Medicaid Services (CMS) Have Issued A Negative Reimbursement Decision in Connection with the National Coverage Determination (NCD) of Epi proColon, Epigenomics' Blood Test for Colorectal Cancer Screening

Epigenomics AG to Report Fiscal Year 2020 Results on Mar 25, 2021

Epigenomics AG Pulls Revenue Guidance for the Year 2020 Due to Covid-19

Epigenomics AG announces the U.S. Centers for Medicare & Medicaid Services have issued a negative reimbursement proposal in connection with the National Coverage Determination of Epi proColon, Epigenomics' blood test for colorectal cancer screening

Epigenomics Ag Pulls Its Revenue Guidance for 2020

Earnings released

New 90-day high - €2.17

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘